In the past two decades, the remarkable improvements by the molecular-targeted therapies have been seen in patients with NSCLC driven by oncogenic alterations, especially in EGFR tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.